Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minExpanding
5 minStrong Bullish
Daily trend turns down below $4.33
Key levels
Resistance$4.33
Resistance$3.85
Support$3.21
Support$2.72
Latest news & SEC filings
EarningsCoya Therapeutics Posts Q3 2026 Results, Issues Business Update
SEC FilingCoya Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All COYA news →Coya Therapeutics is a biotech firm still in the testing phase of development, creating medicines meant to strengthen Tregs, immune cells that hold inflammation in check. Its lead candidate, COYA 302, pairs a small amount of interleukin-2 with another immunomodulatory agent and is under study for ALS and frontotemporal dementia; other programs include COYA 303 for inflammatory conditions and a cell-based therapy using a patient's own Tregs. The company targets neurodegenerative, autoimmune, and metabolic disorders and works mainly within the United States, alongside partners such as Houston Methodist Hospital and Dr. Reddy's Laboratories.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
SEPT Low Target
$12.00
SEPT Mid Target
$14.00
SEPT High Target
$16.00
Analyst Consensus
$14.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for COYA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$11.68
27
Moat Score
NONE
2/9
Piotroski Score
2.8
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
123.6%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-29.59%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for COYA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:55:55 | $3.09 | 2,775 | $$9K | SELL |
| 20:37:11 | $3.21 | 1,000 | $$3K | MIDPOINT |
| 20:34:48 | $3.20 | 1,746 | $$6K | SELL |
| 20:15:32 | $3.24 | 1,500 | $$5K | BUY |
| 20:15:10 | $3.23 | 1,000 | $$3K | SELL |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Coya Therapeutics, Inc. (COYA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Coya Therapeutics, Inc. (COYA) is at $3.27, up 1.87% (+$0.06) at the Nov 12, 2026 close.
Latest COYA news — Nov 10, 2026: Coya Therapeutics Posts Q3 2026 Results, Issues Business Update · Nov 10, 2026: Coya Therapeutics, Inc. filed a report on a major company event (Form 8-K)
The average analyst price target for COYA is $14.00, ranging from $12 to $16, based on 2 analysts.
Analyst ratings for COYA: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
COYA last reported on Aug 11, 2026: EPS -$0.28 vs -$0.35 expected — a beat of 19.0%.
COYA does not currently pay a dividend.
Support: $3.21, $2.72. Resistance: $3.85, $4.33, $4.70.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 10, 2026: Coya Therapeutics Posts Q3 2026 Results, Issues Business Update · Nov 10, 2026: Coya Therapeutics, Inc. filed a report on a major company event (Form 8-K)